Overview on effectiveness of erenumab, fremanezumab, and galcanezumab in reducing medication overuse headache in chronic migraine patients

Article Clinical Neurology

Detoxification vs non-detoxification before starting an anti-CGRP monoclonal antibody in medication overuse headache

Umberto Pensato et al.

Summary: This study suggests that anti-CGRP monoclonal antibodies may be effective in medication overuse headache patients regardless of detoxification, but further research is needed to draw definitive conclusions.

CEPHALALGIA (2022)

添加到收藏夹

Article Clinical Neurology

Real-life assessment of erenumab in refractory chronic migraine with medication overuse headache

Umberto Pensato et al.

Summary: The study found that erenumab significantly reduced migraine frequency and pain medication intake in refractory chronic migraine patients with medication overuse headache. After 3 months, 51% of patients experienced a reduction of at least 50% in monthly headache days, with 20% experiencing a reduction of at least 75%. Allodynia was identified as a negative predictive factor for erenumab response, while 64% of patients clinically converted to episodic migraine without medication overuse.

NEUROLOGICAL SCIENCES (2022)

添加到收藏夹

Review Clinical Neurology

The Evolution of Medication Overuse Headache: History, Pathophysiology and Clinical Update

Christina Sun-Edelstein et al.

Summary: Medication overuse headache (MOH) is a common secondary headache disorder caused by frequent and excessive use of medications for acute headache treatment, potentially facilitating trigeminal nociceptive process through up-regulation of the CGRP system. Recognizing and preventing its development is crucial in migraine management, with ongoing debates over MOH diagnosis, pathogenesis, and treatment strategies. The efficacy of anti-CGRP monoclonal antibodies in MOH suggests potential alternative treatments without the need for detoxification.

CNS DRUGS (2021)

添加到收藏夹

Article Clinical Neurology